Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Total Debt: 2023-2025

Historic Total Debt for Xeris Biopharma Holdings (XERS) over the last 3 years, with Sep 2025 value amounting to $219.5 million.

  • Xeris Biopharma Holdings' Total Debt rose 1357.59% to $219.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.5 million, marking a year-over-year increase of 1357.59%. This contributed to the annual value of $232.1 million for FY2024, which is 10.51% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Total Debt is $219.5 million, which was up 0.39% from $218.6 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Total Debt peaked at $232.1 million during Q4 2024, and registered a low of $420,000 during Q2 2024.
  • Its 3-year average for Total Debt is $106.9 million, with a median of $17.5 million in 2023.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Total Debt slumped by 97.48% in 2024 and then skyrocketed by 51,953.81% in 2025.
  • Over the past 3 years, Xeris Biopharma Holdings' Total Debt (Quarterly) stood at $210.0 million in 2023, then climbed by 10.51% to $232.1 million in 2024, then skyrocketed by 1,357.59% to $219.5 million in 2025.
  • Its Total Debt stands at $219.5 million for Q3 2025, versus $218.6 million for Q2 2025 and $229.8 million for Q1 2025.